COMPANY

Ardelyx

HQ: Fremont, CA source · ardelyx.com ↗ · New England

20 open jobs · last seen Oct 23, 2026 · 31 sources

Profile checked Oct 10, 2026

Keywords: Irritable Bowel Syndrome With Constipation Hyperphosphatemia Constipation Predominant Irritable Bowel Syndrome End Stage Renal Disease Hyperkalemia Chronic Idiopathic Constipation Lactation Chronic Kidney Disease Requiring Chronic Dialysis ESRD Chronic Kidney Disease Type 2 Diabetes Mellitus Tenapanor AZD1722 RDX5791 RDX013 AZD1722 (in-patient) AZD1722 (out-patient) RDX227675

20Open jobs 29Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Area Business Director (Gastroenterology) - Los Angeles, CA	Los Angeles, California	Not stated	Oct 23, 2026
Associate Director, Market Access Training	2 locations (listed on the posting)	Not stated	Oct 14, 2026
Executive Director, Regulatory Affairs	3 locations (listed on the posting)	Not stated	Oct 12, 2026
Senior Investor Relations Manager	Boston, Massachusetts	Not stated	Oct 9, 2026
Director, Analytical Development - Small Molecule	Waltham, Massachusetts	Not stated	Oct 9, 2026

See all 20 jobs

Timeline

Oct 9, 2026 Board tracked Radar started tracking this company’s job board (20 open jobs at last check). source ↗
Feb 24, 2026 Partnership Partnership / licensing announced Feb 24, 2026. Source: company release on GlobeNewswire. source ↗
Jan 13, 2026 Trial start Phase 3: A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults source ↗
Jul 24, 2024 Trial start Phase 2: 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs source ↗
Nov 27, 2023 Trial start Phase 1: An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females source ↗
Feb 17, 2023 Trial start Phase 3: Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C source ↗
Nov 15, 2022 Trial start Phase 3: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years source ↗
Jan 11, 2021 Trial start Phase 2: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia source ↗
Nov 20, 2020 Trial start Phase 4: Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia source ↗
Jun 15, 2019 Trial start Phase 4: A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP source ↗
Feb 28, 2019 Trial start Phase 2/Phase 3: Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy source ↗
Jan 8, 2018 Trial start 3: A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis source ↗
2017-01 Trial start Phase 2: A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia source ↗
2016-03 Trial start Phase 3: A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C source ↗
2016-01 Trial start Phase 3: An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) source ↗
2015-12 Trial start Phase 3: A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C source ↗
2015-10 Trial start Phase 3: A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C source ↗
2014-05 Trial start Phase 1: To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers source ↗
2014-05 Trial start Phase 1: To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers source ↗
2014-04 Trial start Phase 1: AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study source ↗
2014-03 Trial start Phase 2: Dose Finding Study to Treat High Phosphate Levels in the Blood. source ↗
2013-08 Trial start Phase 2/Phase 3: The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) source ↗
2013-07 Trial start Phase 1: Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects source ↗
2013-05 Trial start Phase 2: A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria source ↗
2013-04 Trial start 1: A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722 source ↗

Showing 25 of 31 dated events.

Upcoming milestones

Feb 26, 2027 (ESTIMATED) · Phase 3 · A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults · NCT07382167
2031-07 (ESTIMATED) · Phase 3 · Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C · NCT05905926

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 20

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Area Business Director (Gastroenterology) - Los Angeles, CA	Los Angeles, California	Not stated	Oct 23, 2026	Not stated
Associate Director, Market Access Training	2 locations (listed on the posting)	Not stated	Oct 14, 2026	Senior
Executive Director, Regulatory Affairs	3 locations (listed on the posting)	Not stated	Oct 12, 2026	Executive
Senior Investor Relations Manager	Boston, Massachusetts	Not stated	Oct 9, 2026	Senior
Director, Analytical Development - Small Molecule	Waltham, Massachusetts	Not stated	Oct 9, 2026	Senior
Logistics & Inventory Manager - Pharmaceutical	Newark, California	Not stated	Oct 9, 2026	Mid
Field Reimbursement Manager - Chicago, IL	Chicago, Illinois	Not stated	Oct 9, 2026	Mid
Field Reimbursement Manager - Houston, TX	Houston, Texas	Not stated	Oct 9, 2026	Not stated
Field Reimbursement Manager - Monroe, LA	Monroe, Louisiana	Not stated	Oct 9, 2026	Mid
Field Reimbursement Manager - Philadelphia	Philadelphia, Pennsylvania	Not stated	Oct 9, 2026	Mid
Senior Medical Science Liaison (Gastroenterology) - Texas	4 locations (listed on the posting)	Not stated	Oct 9, 2026	Senior
Associate Director, Quality Auditing & Compliance	2 locations (listed on the posting)	Not stated	Oct 9, 2026	Senior
Executive Director, QMS & Digital - Onsite	Waltham, Massachusetts	Not stated	Oct 9, 2026	Executive
Senior Quality Operations Manager	2 locations (listed on the posting)	Not stated	Oct 9, 2026	Senior
Senior Quality Training Specialist	Waltham, Massachusetts	Not stated	Oct 9, 2026	Senior
Area Business Director (Gastroenterology) - Baltimore, MD	3 locations (listed on the posting)	Not stated	Oct 9, 2026	Senior
Area Business Director (Gastroenterology) - Fresno, CA	Fresno, California	Not stated	Oct 9, 2026	Senior
Area Business Director (Gastroenterology) - Huntington Beach, CA	Huntington Beach, California	Not stated	Oct 9, 2026	Senior
Area Business Director (Gastroenterology) - Long Beach, CA	Long Beach, California	Not stated	Oct 9, 2026	Senior
Area Business Director (Gastroenterology) - Pasadena, CA	Pasadena, California	Not stated	Oct 9, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Last 2 years.

Feb 24, 2026 Partnership / licensing announced Feb 24, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 29

Record	Title	Phase	Status	Start	Primary completion
NCT05643534	Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years	Phase 3	Completed	Nov 15, 2022	Aug 20, 2026 (actual)
NCT06553547	4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs	Phase 2	Completed	Jul 24, 2024	Jul 7, 2026 (actual)
NCT07382167	A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults	Phase 3	Recruiting	Jan 13, 2026	Feb 26, 2027 (estimated)
NCT05905926	Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C	Phase 3	Enrolling by invitation	Feb 17, 2023	2031-07 (estimated)
NCT06203444	An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females	Phase 1	Completed	Nov 27, 2023	May 30, 2024 (actual)
NCT03427125	A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis	3	Completed	Jan 8, 2018	Nov 15, 2019 (actual)
NCT04549597	Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia	Phase 4	Completed	Nov 20, 2020	Oct 13, 2021 (actual)
NCT03988920	A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP	Phase 4	Completed	Jun 15, 2019	Jun 26, 2021 (actual)
NCT03824587	Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy	Phase 2/Phase 3	Completed	Feb 28, 2019	Jul 17, 2019 (actual)
NCT04780841	A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia	Phase 2	Completed	Jan 11, 2021	Dec 28, 2021 (actual)
NCT02081534	Dose Finding Study to Treat High Phosphate Levels in the Blood.	Phase 2	Completed	2014-03	2014-11 (actual)
NCT02727751	A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C	Phase 3	Completed	2016-03	2017-10 (actual)
NCT01764854	Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis	Phase 2	Completed	2013-01	2013-10 (actual)
NCT02675998	An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)	Phase 3	Completed	2016-01	2016-12 (actual)
NCT01847092	A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria	Phase 2	Completed	2013-05	2015-03 (actual)
NCT02686138	A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C	Phase 3	Completed	2015-12	2017-08 (actual)
NCT02621892	A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C	Phase 3	Completed	2015-10	2017-03 (actual)
NCT01923428	The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)	Phase 2/Phase 3	Completed	2013-08	2014-10 (actual)
NCT03018067	A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia	Phase 2	Terminated	2017-01	2017-05 (actual)
NCT01340053	A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)	Phase 2	Completed	2011-05	2011-12 (actual)
NCT02819687	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers	Phase 1	Completed	2010-11	2011-03 (actual)
NCT02796131	Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers	Phase 1	Completed	2011-07	2011-10 (actual)
NCT02063386	AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study	Phase 1	Completed	2014-04	2014-05 (actual)
NCT02226783	D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects	Phase 1	Completed	2013-03	2013-10 (actual)
NCT02140268	To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers	Phase 1	Completed	2014-05	2014-08 (actual)
NCT02140281	To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers	Phase 1	Completed	2014-05	2014-08 (actual)
NCT02346890	A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722	1	Completed	2013-04	2013-04 (actual)
NCT02249936	A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations	1	Completed	2013-02	2013-02 (actual)
NCT02176252	Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects	Phase 1	Completed	2013-07	2013-12 (actual)